Jean-Sébastien Delisle

Office Phone: 514-252-3400 ext.6381
Fax: 514-252-3430
Lab Phone: 514-252-3400 ext. 3365
js.delisle@umontreal.ca

Research Axis  Immunology-Oncology
Research Unit  Cancer Immunology-Transpantation

TITLE

  • Research Professor of medicine

EDUCATION

  • Ph.D., 2005-2010, Université de Montréal
  • Clinical Fellow - Hematopoietic cells transplantation, 2006-2008, Université de Montréal, HMR
  • Hematology Fellow, 2002-2004, McGill University
  • Internal medicine, 1999-2004, McGill University
  • Medicine,  1994-1999, McGill University

DISTINCTIONS AND ACHIEVEMENTS

  • CIHR Clinician-scientist formation award, 2006-2011
  • Training award, FRSQ and secrétariat du sang (MSSS), 2004-2006
  • Elizabeth Ann Munro Gordon Prize – Professionalism and leadership, McGill University, 1999
  • James Mcgill Entrance Scholarship 1994-1999

RESEARCH INTERESTS

The cytokine TGF-beta in immune cell physiology and cancer

The immune system can be remarkably efficient at eliminating several blood cancers, especially in the context of allogeneic hematopoietic cell transplantation. Unfortunately, tumor and immune cell specific factors limit the full potential of immune based therapies of most malignancies. Our work aims at better defining the mechanisms that modulate the anti-tumor response, especially by studying the cancer microenvironment and the potently immunosuppressive cytokine TGF-β. A second research axis focusses on other determinants of T cell physiology in the context of hematopoietic cell transplantation. 

Human T-cell adoptive immunotherapy

Our laboratory is working on the differentiation and expansion of human T cells in vitro in order to support early phase clinical trials at HMR. To this end we have adapted validated culture systems and are currently developing several strategies in order to both increase the therapeutic potency of ex-vivo expanded T cells and study basic aspects of T-cell biology.

RESEARCH TEAM 

  • Cédric Carli, Research Associate
  • Manon Richaud, Research Assistant
  • Julie Taillefer, Research Assistant
  • Amina Dahmani, PhD student
  • Louis-Philippe Caron, M.Sc. Student

Selected papers

  • Janelle V, Carli C, Taillefer J, Orio J, Delisle JS. Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture. J Transl Med. 2015 Apr 19;13:123.
  • Orio J, Carli C, Janelle V, Giroux M, Taillefer J, Goupil M, Richaud M, Roy DC, Delisle JS. Early exposure to interleukin-21 limits rapidly generated anti-Epstein-Barr virus T-cell line differentiation. Cytotherapy. 2015 Apr;17(4):496-508.
  • Krakow EF, Bergeron J, Lachance S, Roy DC, Delisle JS. Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment. Blood Rev. 2014 Nov;28(6):249-61.
  • Delisle JS*, Giroux M*, Hardy MP, Boucher G, Landry JR, Lemieux S, Wilhelm B, Jones R, Perreault C. The TGF-B/Smad3 pathway inhibits CD28-dependent cell growth and proliferation of CD4 T cells.  Genes and Immunity, ePub Jan 2013.
  • Hillhouse E, Delisle JS, Lesage S. Immunoregulatory CD4-CD8- T cells as a potential therapeutic tool for transplantation, autoimmunity and cancer. Frontiers in immunological tolerance, ePub January 2013
  • Carli C, Giroux M, Delisle, JS. The role of TGF-B in the GVH and GVT effects.  Biology of Bone Marrow Transplantation. 2012 Sep;18(9):1329-40.
  • Giroux M*, Delisle JS*, Gauthier SD, Heinonen KM, Hinsinger J, Houde B, Gaboury L, Brochu S, Wu J, Hébert MJ, Perreault C. SMAD3 prevents graft-versus-host disease by restraining Th1 differentiation and granulocyte-mediated tissue damage. Blood. 2010 Nov 30.  * Contribution égale en tant que premiers auteurs
  • Giroux M, Delisle JS O'Brien A, Hébert MJ, Perreault C. T cell activation leads to protein kinase C theta-dependent inhibition of TGF-beta signaling. J Immunol. 2010 Aug 1;185(3):1568-76.
  • Delisle JS, Gaboury L, Bélanger MP, Tassé E, Yagita H, Perreault C. Graft-versus-host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-gamma receptor-deficient hosts. Blood. 2008 Sep 1;112(5):2111-9.
  • Meunier MC, Delisle JS, Baron C, Perreault C. [New hopes for cancerimmunotherapy]. Med Sci (Paris). 2006 Oct;22(10):794-5.
  • Meunier MC, Delisle JS, Bergeron J, Rineau V, Baron C, Perreault C. T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat Med. 2005 Nov;11(11):1222-9.

 Complete list of Dr. Delisle's publications (PubMed) 

ADDITIONAL INFORMATIONs

Grants

    • Hôpital Maisonneuve-Rosemont Foundation
    • Fonds de Recherche en Santé du Québec (FRSQ)
    • Natural Sciences and Engineering Research Council of Canada (NSERC)
    • Stem Cell Network
    • Genome canada
    • Cole Foundation
    • Canadian National Transplant Research Program (CNTRP)/Programme national de recherche en transplantation du Canada